1. Starting dose levels for phase I studies;Verweij,1996
2. Evaluation of preclinical toxicity models for phase I clinical trials of anticancer drugs: The NCI experience (1983–1992);Smith;Proc AACR,1994
3. Drug development within the EORTC;Connors;Proceedings of the 9th NCI/EORTC Symposium on New Drugs in Cancer Therapy,1996
4. Dose-limiting toxicity: Can we make uniform definitions?;Kaye;Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 12–15,1996
5. Filgrastim (r-metHuG-CSF) in the chemotherapy setting;Blackwell,1994